|Bid||18.66 x 800|
|Ask||18.80 x 900|
|Day's range||18.37 - 18.90|
|52-week range||10.81 - 21.25|
|Beta (5Y monthly)||1.17|
|PE ratio (TTM)||N/A|
|Earnings date||28 Feb 2023 - 06 Mar 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||22.50|
The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in Intercept (ICPT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Intercept's (ICPT) new drug application (NDA) for obeticholic acid (OCA) for the treatment of nonalcoholic steatohepatitis gets accepted by the regulatory body in the United States.
NDA is supported by robust NASH clinical development program, including two positive interim analyses from the Phase 3 REGENERATE study demonstrating OCA’s improvement in liver fibrosis without worsening of NASHPDUFA target action date set for June 22, 2023 MORRISTOWN, N.J., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseas